摘要
目的:评价西黄丸/胶囊在临床上辅助治疗乳腺癌的有效性和安全性,以期为临床治疗乳腺癌提供新思路。方法:在PubMed、Embase、the Cochrane Library、中国知网、中国生物医学文献服务系统、万方数据库和维普数据库等数据库中检索自建库以来至2022年12月2日关于西黄丸/胶囊治疗乳腺癌的随机对照试验文献,对检索出的文献进行筛选和数据提取,并使用RevMan 5.4软件进行Meta分析。结果:共纳入12项研究,涉及1260例患者,其中常规治疗+西黄丸/胶囊组637例患者,常规治疗组623例患者。Meta分析结果显示,与常规治疗组比较,常规治疗+西黄丸/胶囊组患者的治疗有效率更高,生活质量评分(卡诺夫斯凯计分、FACT-B评分)更高,免疫细胞指标CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平更高,肿瘤标志物中癌胚抗原(CEA)、糖类抗原153(CA153)和糖类抗原125(CA125)水平更低,差异均有统计学意义(P<0.05);两组患者免疫细胞指标CD8^(+)水平的差异无统计学意义(P>0.05)。安全性方面,常规治疗+西黄丸/胶囊组患者的白细胞减少、血小板减少、胃肠道反应、恶心呕吐和肝肾功能异常等发生情况少于常规治疗组,差异均有统计学意义(P<0.05);但两组患者骨髓抑制发生情况的差异无统计学意义(P>0.05)。结论:西黄丸作为辅助用药联合常规治疗用于乳腺癌患者,可提高治疗有效率、生活质量,提高免疫细胞指标CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平,降低肿瘤标志物CEA、CA125和CA153水平,减少白细胞减少、血小板减少、胃肠道反应、恶心呕吐和肝肾功能异常等情况的发生;但在降低免疫细胞指标CD8^(+)水平、减少骨髓抑制发生等方面无明显优势。
OBJECTIVE:To evaluate the efficacy and safety of Xihuang pills/capsules in the clinical adjuvant treatment of breast cancer,so as to provide new ideas for the clinical treatment of breast cancer.METHODS:PubMed,Embase,the Cochrane Library,CNKI,SinoMed,Wanfang Data and VIP database were retrieved to collect the randomized controlled trials of Xihuang pills/capsules in the clinical adjuvant treatment of breast cancer from the establishment of the database to Dec.2nd,2022.The retrieved literature was screened and data was extracted,and Meta-analysis was performed by using RevMan 5.4.RESULTS:Twelve studies with a total of 1260 patients were included in this study,including 637 patients in the conventional treatment+Xihuang pills/capsules group and 623 patients in the conventional treatment group.Meta-analysis showed that compared with the conventional treatment group,the conventional treatment+Xihuang pills/capsules group had higher treatment effectiveness,higher quality of life score(Kanovsky score,FACT-B score),and higher levels of immune cell indicators CD3^(+),CD4^(+)and CD4^(+)/CD8^(+),lower levels of tumor markers CEA,CA153 and CA125,the differences were statistically significant(P<0.05).There was no significant difference in the levels of immune cell indicator CD8^(+)between two groups(P>0.05).In terms of safety,the leukopenia,thrombocytopenia,gastrointestinal reactions,nausea and vomiting and abnormal liver and kidney function in conventional treatment+Xihuang pills/capsules group were less than those in conventional treatment group,with statistically significant difference(P<0.05).However,there was no significant difference in the occurrence of myelosuppression between two groups(P>0.05).CONCLUSIONS:Xihuang pills,when used as an adjuvant in combination with conventional treatment for patients with breast cancer,can improve the efficacy,quality of life,increase the levels of immune cell indicators CD3^(+),CD4^(+)and CD4^(+)/CD8^(+),reduce the levels of tumor markers CEA,CA125 and CA153,and decrease the occurrence of leukopenia,thrombocytopenia,gastrointestinal reactions,nausea and vomiting,and abnormal liver and kidney function.However,there was no obvious advantage in reducing the level of immune cell indicator CD8^(+)and occurrence of bone marrow suppression.
作者
李会琴
姚丽鸽
张柳艳
王莹杰
李佳音
LI Huiqin;YAO Lige;ZHANG Liuyan;WANG Yingjie;LI Jiayin(Dept.of Medical Oncology,Zhengzhou Third People’s Hospital,Zhengzhou 450000,China)
出处
《中国医院用药评价与分析》
2023年第10期1241-1246,共6页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
西黄丸
西黄胶囊
乳腺癌
META分析
Xihuang pills
Xihuang capsules
Breast cancer
Meta-analysis
